The U.S. Food and Drug Administration has approved Zanvastro (zilganersen), manufactured by Ionis Pharmaceuticals Inc.
A new animal-based study has found GLP-1s could have the potential to do more than curb appetite—they may even extend life ...
Scientists have created an injectable gel that can remain inside arthritic joints for weeks, slowly releasing medication ...
Taiwan clears Lam Research's NT$9.8 billion subsidiary injection as etch leader scales R&D worldwide
Taiwan's Ministry of Economic Affairs has approved a NT$9.835 billion (approx. US$310 million) capital injection by Lam ...
Here’s a look at the most interesting products from the past week, featuring releases from BugBase, F5 Networks, Ping ...
Results from a small trial suggest a modified virus can instruct the immune system to wipe out disease-causing cells.
SpaceX's market cap has returned to $2 trillion by September 2026 after its record $75 billion IPO sparked extreme volatility ...
Large enterprises are rapidly deploying agentic AI, but their autonomy poses significant security risks. Leading experts ...
With the approval of ZANVASTRO, the FDA granted Ionis a Rare Pediatric Disease Priority Review Voucher (PRV), a program ...
WordPress backup plugin vulnerability CVE-2026-19949 in All-in-One WP Migration exposes 3.25 million unpatched sites to ...
Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results